Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Increase in Short Interest

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the recipient of a significant growth in short interest in October. As of October 30th, there was short interest totaling 4,556,267 shares, a growth of 47.4% from the October 15th total of 3,090,758 shares. Based on an average daily trading volume, of 6,864,487 shares, the days-to-cover ratio is presently 0.7 days. Approximately 7.0% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ABOS. BTIG Research dropped their price objective on shares of Acumen Pharmaceuticals to $1.00 and set a “buy” rating for the company in a research note on Monday, November 2nd. Lucid Cap Mkts lowered Acumen Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Citigroup cut Acumen Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a report on Friday, October 30th. Wall Street Zen cut shares of Acumen Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 17th. Finally, Cantor Fitzgerald downgraded shares of Acumen Pharmaceuticals from a “strong-buy” rating to a “strong sell” rating in a report on Friday, October 30th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $1.00.

View Our Latest Research Report on ABOS

Hedge Funds Weigh In On Acumen Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC acquired a new stake in Acumen Pharmaceuticals in the third quarter valued at $192,000. Squarepoint Ops LLC grew its holdings in Acumen Pharmaceuticals by 248.7% in the second quarter. Squarepoint Ops LLC now owns 52,351 shares of the company’s stock valued at $140,000 after purchasing an additional 37,336 shares during the period. Spark Investment Management LLC acquired a new position in shares of Acumen Pharmaceuticals in the 2nd quarter valued at about $39,000. Two Sigma Securities LLC purchased a new position in shares of Acumen Pharmaceuticals in the 2nd quarter valued at $32,000. Finally, Bank of America Corp DE purchased a new position in Acumen Pharmaceuticals in the 2nd quarter worth approximately $734,000. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Acumen Pharmaceuticals Stock Performance

Shares of NASDAQ ABOS traded down $0.01 during midday trading on Tuesday, reaching $0.21. 1,024,850 shares of the stock were exchanged, compared to its average volume of 1,173,056. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 0.17. Acumen Pharmaceuticals has a twelve month low of $0.19 and a twelve month high of $3.60. The firm has a 50-day simple moving average of $1.79 and a two-hundred day simple moving average of $2.39. The firm has a market cap of $15.19 million, a price-to-earnings ratio of -0.13 and a beta of 0.51.

Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) last issued its earnings results on Monday, October 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. As a group, analysts anticipate that Acumen Pharmaceuticals will post -1.50 EPS for the current fiscal year.

Acumen Pharmaceuticals Company Profile

(Get Free Report)

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease. Its research focuses on soluble amyloid beta oligomers, forms of the protein that the company believes contribute to the disease. The company’s lead investigational product, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target amyloid beta oligomers. Acumen has evaluated the treatment in clinical studies of people with early Alzheimer’s disease; it is investigational and has not been approved for commercial use.

See Also

Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.